Martin Gill

Martin Gill has worked in a variety of roles in the scientific field since 2005. Martin began their career as a Research Scientist at UTMB, working under the direction of J. Regino Perez-Polo, Ph. D. In 2007, they moved to Northwestern University, Feinberg School of Medicine, where they held the role of Postdoctoral Research Scientist, managed by Geoffrey T. Swanson, Ph. D. In 2009, they became a Research Scientist/Postdoctoral Fellow at Eli Lilly and Company, managed by David S. Bredt, M. D. In 2011, they were hired by Bristol-Myers Squibb as a Senior Research Investigator, managed by Angela M. Cacace, Ph. D. In 2016, they joined Neuropore Therapies, Inc. as Senior Director of Drug Discovery, and later held the role of Senior Director, Drug Discovery, managed by Douglas W. Bonhaus, Ph. D. Most recently, in 2021, Martin was hired as Vice-President and Head of Biology at Libra Therapeutics.

Martin Gill obtained a Doctor of Philosophy (Ph.D.) in Neurobiology and Neurosciences from The University of Texas Medical Branch.